| Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ... Journal of Clinical Oncology 36 (24), 2532-2537, 2018 | 471 | 2018 |
| The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution O Rozenblatt-Rosen, A Regev, P Oberdoerffer, T Nawy, A Hupalowska, ... Cell 181 (2), 236-249, 2020 | 398 | 2020 |
| High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden R Benayed, M Offin, K Mullaney, P Sukhadia, K Rios, P Desmeules, ... Clinical Cancer Research 25 (15), 4712-4722, 2019 | 362 | 2019 |
| Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers M Offin, H Rizvi, M Tenet, A Ni, F Sanchez-Vega, BT Li, A Drilon, MG Kris, ... Clinical Cancer Research 25 (3), 1063-1069, 2019 | 309 | 2019 |
| COVID-19 in patients with lung cancer J Luo, H Rizvi, IR Preeshagul, JV Egger, D Hoyos, C Bandlamudi, ... Annals of Oncology 31 (10), 1386-1396, 2020 | 298 | 2020 |
| Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer AJ Schoenfeld, JM Chan, D Kubota, H Sato, H Rizvi, Y Daneshbod, ... Clinical Cancer Research 26 (11), 2654-2663, 2020 | 281 | 2020 |
| Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes M Offin, JM Chan, M Tenet, HA Rizvi, R Shen, GJ Riely, N Rekhtman, ... Journal of Thoracic Oncology 14 (10), 1784-1793, 2019 | 278 | 2019 |
| PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers JK Sabari, GC Leonardi, CA Shu, R Umeton, J Montecalvo, A Ni, R Chen, ... Annals of Oncology 29 (10), 2085-2091, 2018 | 270 | 2018 |
| Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer JM Chan, A Quintanal-Villalonga, VR Gao, Y Xie, V Allaj, O Chaudhary, ... Cancer cell 39 (11), 1479-1496. e18, 2021 | 210 | 2021 |
| HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ... Cancer discovery 10 (5), 674-687, 2020 | 195 | 2020 |
| Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET–rearranged lung cancers A Drilon, JJ Lin, T Filleron, A Ni, J Milia, I Bergagnini, V Hatzoglou, ... Journal of Thoracic Oncology 13 (10), 1595-1601, 2018 | 173 | 2018 |
| Immunophenotype and response to immunotherapy of RET-rearranged lung cancers M Offin, R Guo, SL Wu, J Sabari, JD Land, A Ni, J Montecalvo, ... JCO precision oncology 3, 2019 | 126 | 2019 |
| A prospective study of circulating tumor DNA to guide matched targeted therapy in lung cancers JK Sabari, M Offin, D Stephens, A Ni, A Lee, N Pavlakis, S Clarke, ... JNCI: Journal of the National Cancer Institute 111 (6), 575-583, 2019 | 123 | 2019 |
| Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors D Liu, M Offin, S Harnicar, BT Li, A Drilon Therapeutics and clinical risk management, 1247-1252, 2018 | 120 | 2018 |
| Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer K Suzawa, M Offin, D Lu, C Kurzatkowski, M Vojnic, RS Smith, JK Sabari, ... Clinical Cancer Research 25 (4), 1248-1260, 2019 | 113 | 2019 |
| Impact of enhanced mobilization of bone marrow derived cells to site of injury EJ Hannoush, ZC Sifri, IO Elhassan, AM Mohr, WD Alzate, M Offin, ... Journal of Trauma and Acute Care Surgery 71 (2), 283-291, 2011 | 105 | 2011 |
| Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancers M Offin, D Feldman, A Ni, ML Myers, WV Lai, E Pentsova, A Boire, ... Cancer 125 (24), 4380-4387, 2019 | 103 | 2019 |
| Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers M Offin, R Somwar, N Rekhtman, R Benayed, JC Chang, A Plodkowski, ... JCO Precision Oncology 2, 1-12, 2018 | 97 | 2018 |
| Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation A Quintanal-Villalonga, H Taniguchi, YA Zhan, MM Hasan, SS Chavan, ... Cancer discovery 11 (12), 3028-3047, 2021 | 85 | 2021 |
| Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers M Vojnic, D Kubota, C Kurzatkowski, M Offin, K Suzawa, R Benayed, ... Journal of Thoracic Oncology 14 (5), 802-815, 2019 | 83 | 2019 |
